Breast Cancer
Conditions
Brief summary
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).
Interventions
DRUGOnartuzumab
Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
DRUGBevacizumab
Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
DRUGPaclitaxel
Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
DRUGBevacizumab Placebo
Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
DRUGOnartuzumab Placebo
Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Sponsors
Hoffmann-La Roche
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Histologically confirmed estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor 2 (HER2)-negative (triple-negative) adenocarcinoma of the breast * Confirmed availability of tumor tissue
Exclusion criteria
* Prior therapy with two or more regimens for metastatic breast cancer * Any systemic anti-cancer therapy within 3 weeks prior to Day 1 of Cycle 1 * Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1 of Cycle 1 * Prior therapy with a taxane for metastatic breast cancer * Prior therapy with bevacizumab, sorafenib, sunitinib, or other putative vascular endothelial growth factor (VEGF) pathway-targeted therapy following diagnosis of breast cancer * Prior therapy with hormones and/or trastuzumab * Inadequate hematology, renal, or hepatic organ function Bevacizumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants Who Have not Received Prior Systemic Therapy or Have Progressed to Prior First-line Treatment | From randomization until disease progression (PD), relapse, or death on study (within 30 days of last study drug administration) from any cause, whichever occurs first (to be assessed according to local standard of care overall up to 5 years) |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants With Objective Response as Assessed by the Investigator According to RECIST v1.1 | From randomization until PD, relapse, or death on study from any cause, whichever occurs first (to be assessed according to local standard of care overall up to 5 years) |
| Duration of Response as Assessed by the Investigator Using RECIST v1.1 | From initial objective response to PD or death on study from any cause, whichever occurs first (to be assessed according to local standard of care overall up to 5 years) |
| Overall Survival (OS) | From randomization until death from any cause, loss to follow-up, study termination by sponsor, or participant's withdrawal in survival follow-up (overall up to 5 years) |
| PFS According to RECIST v1.1 in Participants Who Have not Received Prior Systemic Therapy | From randomization until PD, relapse, or death on study from any cause, whichever occurs first (to be assessed according to local standard of care overall up to 5 years) |
| Number of Cycles of Treatment Received for Onartuzumab, Paclitaxel, and Bevacizumab During the Study | Day 1 Cycle 1 (cycle length=28 days) up to last dose of study drug or study discontinuation/termination, whichever is later (overall up to 5 years) |
| Percentage of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab | Predose on Day 1 of Cycles 1-4 (cycle length=28 days), 30 days after last administration of onartuzumab or initiation of another therapy (overall up to 5 years) |
| Serum Levels of ATAs Against Onartuzumab | Predose on Day 1 of Cycles 1-4 (cycle length=28 days), 30 days after last administration of onartuzumab or initiation of another therapy (overall up to 5 years) |
| Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs) | Day 1 Cycle 1 (cycle length=28 days) up to 30 days after last dose of study drug or study discontinuation/termination, whichever is later (overall up to 5 years) |
Countries
Belgium, France, Germany, Spain, United Kingdom, United States
Outcome results
None listed